Drug | Antibody (marker) | Rx line | Tumor type | Targeted cells | Tumor specimen | Cutoff point (%) | ORR % in IHC+ cases (95 % CI) | ORR % in IHC− cases (95 % CI) | Predictive role | P value | References |
---|---|---|---|---|---|---|---|---|---|---|---|
Nivolumab | 28-8 rabbit (Dako) | 1Â L | Melanoma | TCs | Archival FFPE or new biopsy | 5 | 58 (46,69) | 41 (35,48) | Yes | 0.001 | Larkin J (2015) [130] |
Nivolumab + ipilimumab | 72 (60,82) | 55 (48,62) | Yes | 0.001 | |||||||
Nivolumab | ≥2 L | 5 | 44 (30,58) | 20 (11,32) | Yes | NA | Weber JS (2015) [128] | ||||
Nivolumab + ipilimumab | 1 L | 5 | 58 (37,78) | 55 (42,69) | No | >0.05 | Postow MA (2015) [4] | ||||
Nivolumab | 1Â L | 5 | 53 (41,64) | 33 (25,42) | No | >0.05 | Robert C (2015) [129] | ||||
≥2 L | NSCLC | TCs | Archival FFPE or new biopsy | 1 | 31 (23,40) | 9 (5,16) | Yes | 0.002 | |||
5 | 36 (26,46) | 10 (6,17) | Yes | 0.002 | |||||||
10 | 37 (27,48) | 11 (6,17) | Yes | 0.002 | |||||||
≥2 L | Archival FFPE | 1 | 17 (9,29) | 17 (8,29) | No | 0.9364 | Brahmer JR (2015) [125] | ||||
5 | 21 (10,37) | 15 (8,25) | No | 0.2908 | |||||||
10 | 19 (8,36) | 16 (9,26) | No | 0.6411 | |||||||
≥2 L | Archival FFPE | 1 | 20 (5,35) | 13 (2,28) | No | >0.05 | Rizvi NA (2015) [131] | ||||
5 | 24 (5,43) | 14 (3,25) | No | ||||||||
1Â L | Archival FFPE | 5 | 31 (NA) | 10 (NA) | No | >0.05 | Gettinger SN (2015) [157] | ||||
Nivolumab + ipilimumab | 1 L | Archival FFPE | 5 | 19 (NA) | 14 (NA) | No | >0.05 | Antonia SJ (2014) [158] | |||
Nivolumab | 5H1 and anti-PD-1 monoclonal M3 | ≥2 L | Archival FFPE | 5 | 39 (34,44) | 6 (1,12) | Yes | 0.025 | Taube JM (2014) [113] | ||
Pembrolizumab | 22C3 mouse (Dako) | ≥1 L | NSCLC | TCs and ICs | New biopsy | 50 | 45 (33,57) | 17 (10,25) | Yes | 0.001 | Garon EB (2015) [5] |
1Â L | New biopsy | 50 | 47 (23,72) | 19 (8,38) | Yes | NA | Rival NA (2015) [159] | ||||
Any | Archival FFPE | 1 | 25 (NA) | 13 (NA) | Yes | NA | Garon EB (2014) [160] | ||||
≥1 L | Archival FFPE | 50 | 30 (23,39) | 9.8 (NA) | Yes | NA | Herbst RS (2015) [140] | ||||
29 (22,37) | 10.7 (NA) | ||||||||||
1Â L | Archival FFPE | 50 | 16 (NA) | 10 (NA) | Yes | NA | Garon EB (2014) [161] | ||||
Atezolizumab (MPDL3280A) | SP142 rabbit (Roche Ventana) | ≥2 L | NSCLC | TCs and ICs | Archival FFPE and new biopsy | 50 | 45 (23,68) | 14 (6,25) | Yes | NA | Leora H (2015) [162] |
≥2 L | NSCLC | 1+ | 31 (25,37) | 20 (14,26) | Yes | 0.015 | Herbst RS (2014) [145] | ||||
Solid Tumor | 1+ | 29 (27,31) | 13 (10,16) | Yes | 0.007 | ||||||
≥2 L | NSCLC | 2+ | 18 (NA) | 8 (NA) | Yes | NA | Spira AI (2015) [143] | ||||
Durvalumab (MEDI-4736) | SP263 rabbit (Roche Ventana) | ≥2 L | NSCLC | TCs | Archival FFPE and new biopsy | 25 | 39 (NA) | 5 (NA) | Yes | NA | Segal NH (2014) [163] |
33 (13,59) | 30 (16,47) | No for combo | NA | Antonia SJ (2016) [155]; | |||||||
22 (3, 60) | 29 (8, 58) | No for monotherapy | NA |